The treatment of polycystic ovary syndrome.
D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use; D000077465:Cabergoline; D002318:Cardiovascular Diseases / Q000150:complications; D002996:Clomiphene / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use; D048909:Diabetes Complications; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D018120:Finasteride / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D006062:Gonadotropins / Q000627:therapeutic use; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009765:Obesity / Q000150:complications / Q000628:therapy; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D012307:Risk Factors; D013148:Spironolactone / Q000627:therapeutic use; D015431:Weight Loss
D000726:Androgen Antagonists; D018491:Dopamine Agonists; D004873:Ergolines; D006062:Gonadotropins; D007004:Hypoglycemic Agents; D000451:Mineralocorticoid Receptor Antagonists; D002996:Clomiphene; D013148:Spironolactone; D017373:Cyproterone Acetate; D018120:Finasteride; D005485:Flutamide; D005640:Follicle Stimulating Hormone; D008687:Metformin; D000077465:Cabergoline